Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | Journal Article |
PMID | (30253346) |
Authors | Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q |
Title | Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. |
Journal | European journal of medicinal chemistry |
Vol | 158 |
Issue | |
Date | 2018 Oct 05 |
URL | |
Abstract Text | Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300-10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JSH-150 | CDK9 Inhibitor 17 | JSH-150 selectively inhibits CDK9, potentially resulting in increased cell-cycle arrest and decreased proliferation of tumor cells (PMID: 30253346). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | B-cell lymphoma | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 inhibited proliferation of a B-cell lymphoma cell line in culture (PMID: 30253346). | 30253346 |
Unknown unknown | acute myeloid leukemia | not applicable | JSH-150 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, JSH-150 induced cell-cycle arrest and inhibited proliferation of acute myeloid leukemia cell lines in culture, and inhibited tumor progression in xenograft models (PMID: 30253346). | 30253346 |
Unknown unknown | melanoma | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 inhibited proliferation of a melanoma cell line in culture (PMID: 30253346). | 30253346 |
Unknown unknown | colon cancer | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 inhibited proliferation of a colon cancer cell line in culture (PMID: 30253346). | 30253346 |
Unknown unknown | neuroblastoma | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 inhibited proliferation of a neuroblastoma cell line in culture (PMID: 30253346). | 30253346 |
Unknown unknown | chronic lymphocytic leukemia | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 induced cell-cycle arrest and inhibited proliferation of chronic lymphocytic leukemia cell lines in culture (PMID: 30253346). | 30253346 |
Unknown unknown | gastrointestinal stromal tumor | not applicable | JSH-150 | Preclinical - Cell culture | Actionable | In a preclinical study, JSH-150 inhibited proliferation of a gastrointestinal stromal tumor cell line in culture (PMID: 30253346). | 30253346 |